EXCESS COSTS ASSOCIATED WITH POSSIBLE MISDIAGNOSIS OF ALZHEIMER'S DISEASE AMONG PATIENTS WITH VASCULAR DEMENTIA IN ITALY
Author(s)
Barrett A1, Belger M1, Dell'Agnello G2, Mancini M2, Reed C1, Sangiori D3, Blini V4, Buda S3, Esposti LD5, Happich M6
1Eli Lilly and Company Ltd, Windlesham, UK, 2Eli Lilly Italia S.p.A., Sesto Fiorentino - FI, Italy, 3CliCon S.r.l., Ravenna, Italy, 4CliCon S.r.l., RAVENNA, Italy, 5CliCon Srl, Ravenna, Italy, 6Lilly Deutschland GmbH, Bad Homburg, Germany
OBJECTIVES: The objective of this study was to evaluate health care costs over time in patients diagnosed with vascular dementia (VD) who had a prior diagnosis of Alzheimer’s disease (AD) compared with similar patients with no prior diagnosis of AD in patients in Italy. METHODS: A cohort of patients whose most recent diagnostic records for dementia indicated presence of VD was identified from administrative databases of a sample of Italian Local Health Units. VD patients were required to have no indication for other dementia types between their earliest indication of cognitive decline or earliest VD diagnosis (index date) and their most recent VD diagnoses and to have continuous data visibility for ≥6 months prior to the index date. The cohort was then categorised based on diagnosis of AD prior to their first confirmed VD diagnosis, and followed for up to 3 years post-index. Patients with prior AD were matched to similar patients with no prior AD using propensity score methods. Annual healthcare costs were calculated for the two cohorts. RESULTS: Of the 2652 VD patients, who were primarily identified in a hospital setting, 103 (4%) had prior AD diagnoses. All 103 patients with prior AD were successfully matched (ratio 1:5) for the cost analysis. Patients with prior AD misdiagnosis had higher annual healthcare costs over the follow up period compared to those patients without prior diagnosis. For patients with 3 years of follow-up average health care costs (95% Confidence limits) per patient with prior AD diagnosis were €10,899(7410, 14387), €5256(2578, 7754), €4409 (2090, 6727) in years 1, 2 and 3 respectively, compared to €8196(6652, 9741), €3404(2177, 4632) and €2770(1958, 3582) in the no prior AD cohort. CONCLUSIONS: This retrospective analysis suggests that possible misdiagnosis of AD among Italian patients with VD results in greater health care costs.
Conference/Value in Health Info
2015-11, ISPOR Europe 2015, Milan, Italy
Value in Health, Vol. 18, No. 7 (November 2015)
Code
PND27
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Neurological Disorders